Medtech Trends 2026: Reshaping Healthcare and Industrial Strategy Across Eurasia

As global medtech undergoes structural change, Eurasia must adapt to new pricing dynamics, supply chain pressures, and digital platforms. The region's response will shape its healthcare systems, industrial competitiveness, and economic integration.

Executive Summary

The medical technology (medtech) sector is entering a period of accelerated transformation driven by global pricing reforms, shifts in care delivery, supply chain volatility, metabolic disease management, and enabling technologies. While these trends are global in scope, they carry distinct implications for Eurasia – a region increasingly central to cross-border trade, manufacturing, and digital innovation. China's volume-based procurement (VBP) expansion is redefining market economics and influencing regional pricing expectations. The migration of procedures to outpatient settings signals a need for healthcare infrastructure modernization. Tariff exposure and geopolitical tensions are prompting a reevaluation of manufacturing footprints, reinforcing the strategic importance of Eurasian supply chain routes, including the Middle Corridor. The rapid adoption of GLP-1 therapies is altering care pathways for metabolic diseases, creating new demand for medical devices and monitoring technologies. Finally, platform-based competition, powered by AI and digital workflows, is reshaping how medtech companies deliver value, opening opportunities for Eurasian innovators to participate in regional and global ecosystems.

For Eurasian policymakers, investors, and businesses, these trends underscore the importance of investing in healthcare infrastructure, fostering industrial resilience, and embracing digital transformation. The region's ability to integrate these forces into a coherent development strategy will be critical to its long-term competitiveness and economic diversification.

Introduction

Eurasia occupies a unique position in the global economy, bridging Europe and Asia through trade corridors, energy routes, and increasingly interconnected supply chains. As the medtech industry navigates the most consequential changes in a generation, the region must assess how global trends interact with its own ambitions for economic modernization and regional integration. From Central Asia's emerging healthcare markets to the Caucasus's growing role in logistics and the European Union's eastern frontier, the medtech landscape of 2026 will be shaped by decisions made today.

This analysis draws on key trends identified by Clarivate's Medtech Trends to Watch 2026 report, interpreting them through a Eurasian lens. It provides a strategic overview of what businesses, investors, and policymakers should expect and how they can position themselves for the challenges and opportunities ahead.

Main Analysis

1. China's VBP Expansion and the New Pricing Reality

Mainland China's national volume-based procurement (VBP) program has evolved from a cost-containment measure into a market-structuring force. The latest rounds feature more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. This has direct and indirect consequences for Eurasian medtech markets. Countries in Central Asia and the Caucasus that rely on imported medical devices will likely see cheaper Chinese products, but also a narrowing of options from multinational companies that may exit less profitable segments. The pricing expectations set by VBP are likely to influence procurement negotiations in other emerging markets, pressuring margins for Western manufacturers and creating space for regional competitors.

For Eurasian medical device distributors and healthcare providers, the trend signals a need to diversify suppliers and prepare for a more fragmented pricing environment. Regional governments engaged in cross-border trade with China – especially through economic corridors like the China-Central Asia-West Asia corridor – should monitor VBP's evolution as it will shape import structures and product availability.

2. Outpatient Migration and Infrastructure Implications

While the U.S. Centers for Medicare & Medicaid Services (CMS) policy explicitly expands ambulatory surgical center (ASC) eligibility, the broader shift of procedures from hospital settings to outpatient environments is a global phenomenon. In Eurasia, healthcare systems vary widely in maturity. Western European countries are already adjusting to same-day surgery models, while Central Asian states are still building basic infrastructure. The trend toward outpatient care will increase demand for medical equipment suited to smaller facilities, such as diagnostic imaging, minimally invasive surgical tools, and monitoring devices. This presents an opportunity for Eurasian manufacturers to invest in tailored product lines and for governments to design healthcare policies that support decentralized service delivery.

For the region's construction and infrastructure sectors, the shift will spur investments in outpatient clinics, diagnostic centers, and integrated healthcare complexes. These projects align with broader regional connectivity initiatives, as improved healthcare infrastructure can attract medical tourism and skilled labor, reducing brain drain.

3. Supply Chains and the Case for Regional Manufacturing

Global supply chain pressure is one of the most defining medtech industry trends. Tariff exposure, geopolitical factors, and fluctuating material costs are forcing companies to rethink manufacturing footprints. This is where Eurasia's strategic importance becomes paramount. The Middle Corridor – the trade route linking China to Europe via Central Asia, the Caucasus, and Türkiye – offers an alternative to maritime routes and is gaining traction as a reliable, time-efficient passage for cargo. Medtech manufacturers seeking multi-region production footprints are likely to explore opportunities in Türkiye, Georgia, Azerbaijan, and Kazakhstan, leveraging their access to raw materials, energy resources, and proximity to both major markets.

The desire for supply chain resilience also extends to components and raw materials. Rare earth elements, specialty metals, and polymers used in medical devices are available across the region, creating potential for local vertical integration. Governments aiming to attract foreign direct investment in medtech manufacturing should emphasize their comparative advantages, including energy costs, logistical hubs, and free trade agreements. For example, Georgia's deep-water ports and Türkiye's customs union with the EU offer unique benefits for companies seeking to serve both Western and Eastern markets.

4. GLP-1 Therapies and the Changing Metabolic Care Landscape

The explosive growth of glucagon-like peptide-1 (GLP-1) receptor agonists is transforming treatment of obesity, diabetes, and associated comorbidities. While these are pharmacological interventions, their widespread adoption alters demand for medical devices used in weight management, bariatric surgery, and monitoring of metabolic health. In Eurasia, the prevalence of obesity and type 2 diabetes is rising, particularly in Eastern Europe and Central Asia. This will increase demand for continuous glucose monitors, insulin pumps, and diagnostic tools. However, the relatively high cost of GLP-1 therapies may limit access, creating a two-tier system where wealthy patients opt for pharmacological treatment while others rely on surgical and device-based interventions.

For regional medtech companies, this represents a strategic opening. They can develop cost-effective devices and digital health solutions that support metabolic care in resource-constrained settings. Partnerships with pharmaceutical distributors and telemedicine platforms could create integrated care pathways that improve outcomes while managing costs.

5. Platform-Based Medtech and the Digital Opportunity

Enabling technologies – robotics, imaging, navigation, and digital workflow software – are converging into platforms that anchor entire service lines. These platforms leverage artificial intelligence and data analytics to improve clinical decision-making and operational efficiency. For Eurasia, this trend intersects with national digital transformation agendas. Several governments have adopted AI and digital health strategies, but many lag in infrastructure and regulatory readiness.

Innovation hubs in Türkiye, Armenia, and Kazakhstan are nurturing medtech startups focused on telemedicine, AI diagnostics, and remote patient monitoring. The challenge lies in scaling these innovations to compete with global platforms. Regional cooperation is crucial. Pooling data resources, harmonizing regulations, and creating joint research initiatives could enable the emergence of Eurasian platforms that serve local languages and cultural contexts. Private equity and venture capital interest in the region is growing, but investors require stable intellectual property protection and transparent regulatory pathways.

Business Impact

For established medical device companies operating in Eurasia, the key implications are:

• Pricing pressure: VBP-induced price reductions will spill over, compelling companies to adjust pricing strategies and product portfolios for lower-margin markets.
• Supply chain redesign: Companies must evaluate manufacturing locations, logistics routes, and supplier diversification. The Middle Corridor and other Eurasian transit options will play a role in mitigating disruptions.
• Commercial model adaptation: The shift to outpatient care and digital platforms requires new sales channels, customer segmentation, and service-based offerings.
• Innovation focus: Investments in AI, robotics, and digital health should be aligned with local demand and regulatory frameworks. Partnerships with regional tech ecosystems can accelerate time-to-market.

For local manufacturers, the trends offer a window to gain market share by producing affordable alternatives and participating in global supply chains. Governments that create favorable investment conditions – via economic zones, tax incentives, and trade agreements – will attract both foreign and domestic capital into medical device production.

Regional Perspective

The impact of these trends will vary across Eurasia's sub-regions:

• European Union: Eastern EU member states, such as Poland, Romania, and Bulgaria, are becoming hubs for medical device manufacturing, driven by labor costs and proximity to Western markets. They will benefit from supply chain diversification but face pressure to maintain technological competitiveness.
• Türkiye: A strong industrial base and a young population position Türkiye as a potential medtech exporter. Its manufacturing capabilities in advanced machinery and electronics can support device production, while its bridges between Asia and Europe make it a logistics linchpin.
• Central Asia: Kazakhstan and Uzbekistan are developing healthcare infrastructure and may attract investment in manufacturing via the Middle Corridor. However, regulatory harmonization and skilled labor shortages remain constraints.
• Caucasus: Georgia, Azerbaijan, and Armenia are leveraging their connectivity and business-friendly reforms to attract medtech trade and investment. However, geopolitical tensions can undermine predictability.
• Western Balkans: Countries in this region are aligning with EU norms, making them attractive for suppliers seeking to integrate into European value chains.

Regional cooperation frameworks, including the Organization of Turkic States and the Black Sea Economic Cooperation, can facilitate joint initiatives in standards alignment, research, and infrastructure development. The development of regional health data spaces could enable AI applications while protecting patient privacy.

Future Outlook

Looking ahead to 2026 and beyond, Eurasia will see:

• Growth in medical device imports and domestic production as healthcare demand rises and procurement systems modernize.
• Deeper integration with global supply chains, particularly along the Middle Corridor and other East-West routes, as medtech companies adopt multi-regional footprints.
• Digital health acceleration, with telemedicine and AI diagnostics becoming standard in urban centers and expanding to rural areas through mobile networks.
• Increased public and private investment in healthcare infrastructure, powered by public-private partnerships and development finance from institutions like the European Bank for Reconstruction and Development.
• Potential for an Eurasian medtech innovation ecosystem, if governments invest in education, intellectual property enforcement, and cross-border data governance.

The next three to five years are pivotal. Eurasia's ability to anticipate and respond to these trends will determine whether it becomes an integral part of the global medtech value chain or remains a peripheral consumer market.

Conclusion

The medtech trends of 2026 are not confined to any single region; they will ripple worldwide. For Eurasia, they represent both a challenge and an opportunity. By understanding the forces shaping global pricing, supply chains, care delivery, and technology, stakeholders across the region can make strategic decisions that enhance resilience, competitiveness, and integration. Governments, businesses, and investors must act in concert, leveraging Eurasia's unique geographic and economic position to transform healthcare and industrial ambitions into tangible outcomes.

Key Takeaways

• China's VBP expansion is a global pricing driver, affects Eurasian imports, and creates opportunities for domestic manufacturers in cost-competitive segments.
• The shift to outpatient care demands investments in healthcare infrastructure and equipment designed for smaller facilities.
• Supply chain pressures are boosting the strategic relevance of the Middle Corridor and regional manufacturing hubs.
• GLP-1 therapies will increase demand for metabolic monitoring devices, especially in cost-sensitive markets.
• Platform-based medtech, including AI and digital workflows, offers new opportunities for Eurasian innovators to leapfrog older technologies.
• Regional collaboration in regulation, data sharing, and infrastructure investment is essential to capitalize on these trends.

Sources

• Clarivate. "Medtech Trends to Watch in 2026." Accessed at: https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026